NasdaqGS:AMRXPharmaceuticals
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Strong 2025 Results And 2026 Growth Guidance
Amneal Pharmaceuticals (AMRX) is back in focus after reporting 2025 results, with revenue of US$3.02b, operating income of US$421m, and lower net leverage of 3.5x, alongside 2026 guidance pointing to adjusted EBITDA and EPS growth.
See our latest analysis for Amneal Pharmaceuticals.
The recent pullback, including a 16.4% 1 month share price return decline to US$12.39, sits against a much stronger backdrop. The 1 year total shareholder return is 41.9%, and the 3 year total shareholder return...